CIBELES: Xience V comparative study vs Cypher for the treatment of total chronic occlusions.

Spanish-Portuguese multicentre CIBELES study (Raul Moreno, Madrid, Spain) compared two drug-eluting stents – an everolimus (Xience V, Abbott Vascular, USA) and a sirolimus-releasing eluting stent (Cypher Select, Cordis Corporation, Miami Lakes, Florida, USA) in the context of total chronic coronary occlusions. With a non-inferiority design, the study randomized 208 patients (1:1), using as the primary endpoint a late loss in-stent at 9 months.

Conclusion: Xience stent proved to be non-inferior to Cypher stent in the context of total chronic occlusions.

Moreno-CIBELES
Raúl Moreno
2012-05-17

More articles by this author

EVOLUTION: Comparative study of non-inferiority of two sirolimus eluting stents: One with permanent polymer and the other with degradable polymer.

The EVOLUTION study, (Dr. Junbo Ge, Shanghai Institute, China), compared two sirolimus-eluting stents, one with permanent polymer (Cypher Select, Cordis Corporation, Miami Lakes, Florida,...

SORT OUT V: Comparison of drug-eluting stents: One with degradable polymer releasing biolimus and the other a permanent polymer sirolimus stent.

SORT OUT V randomized trial (Odense University Hospital, Denmark) compared Nobori stent, a drug-eluting stent with biodegradable polymer eluting biolimus, versus CYPHER a drug-eluting...

ROMA II RELOAD: Additional charge of statin (rosuvastatin 40 mg or atorvastatin 80 mg within 24 hours of procedure) in patients on whom elective...

ROMA II RELOAD multicenter study (General Hospital Umberto I, University of Rome, Rome, Italy) assessed the impact of an additional charge of statin in...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...